Online ISSN: 2515-8260

Keywords : Total parotidectomy

Total conservative parotidectomy for management of benign parotid neoplasms

Dr. Apurva Agarwal, Dr. Manas Ranjan Deo, Dr. Santsevi Prasad, Dr. Sunil Kumar

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 1422-1426

Introduction: Salivary gland tumours contribute for about 3 - 10% of all neoplasms of the
head and neck; from this, benign tumours are commoner than their malignant counterpart.
The most common benign neoplasm of salivary glands is pleomorphic adenoma which
constitute about 60 – 70% incidence in the general population. The overall incidence of
salivary gland tumours is roughly remains unchanged throughout the world and there is no
significant predilection for either sex. In the early 1940s, intracapsular enucleation was
performed as the management for pleomorphic adenoma. Leaving the tumour capsule in-situ
resulted with 45% of its recurrence. Patey and Thackray explained that the capsule of the
tumour is often incomplete and therefore, a lumpectomy was suggested to be replaced by
other procedures available. Extra capsular dissection removes 2–3 mm border of healthy
tissues without damaging the facial nerve and partial superficial parotidectomy removes 2 cm
of normal parotid tissue with partial facial nerve dissection. Furthermore, SP versus TCP
carries the advantages of avoiding post-operative temporary facial nerve weakness and Frey’s
syndrome. Hence, there is also evidence that 60% of parotid tumours lie in close contact with
facial nerve and exposure of the tumour capsule remains a great concern.3 this retrospective
study assesses the immediate and long-term results of Total Conservative Parotidectomy in
patients with benign parotid neoplasms.